Induced pluripotent stem cells (iPSC) shown to form multiple types of functional lymphocytes in vivo
New Rochelle, NY, March 28, 2016 — A new study demonstrates that iPSC have the potential to differentiate into multiple lineages of functional lymphocytes, including CD4+ T cells, B cells, and natural killer cells, without bias. The ability to generate truly functional lymphocytes from somatic cell-derived hematopoietic stem cells supports the clinical application of iPSC technology to develop treatments for hematological disorders, as concluded in the study published in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Stem Cells and Development website until April 28, 2016.
Tianshu Lan and coauthors from Medical College of Xiamen University (Xiamen City) and Chinese Academy of Sciences (Beijing), China, provided a normal environment in which to compare the growth and differentiation capacity of hematopoietic cells derived from IPSC and from embryonic stem cells (ESC). The results show that lymphocytes generated from iPSC had the same capacity to proliferate and secrete chemical signals such as cytokines as did those from ESC when stimulated.
In the article "Induced Pluripotent Stem Cells Can Effectively Differentiate into Multiple Functional Lymphocyte Lineages In Vivo with Negligible Bias", the researchers further report that lymphocytes generated by iPSC-derived bone marrow cells could repopulate the hematopoietic systems of lethally irradiated recipient animals.
"This sort of side-by-side characterization and demonstration of the differential potential of iPSC and ESC is an absolute necessity to elevate what we do in stem cell research from conjecture and assumption to rigorous applicability and then clinical translation," says Editor-in-Chief Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.
About the Journal
Stem Cells and Development is an authoritative peer-reviewed journal published 24 times per year in print and online. The Journal is dedicated to communication and objective analysis of developments in the biology, characteristics, and therapeutic utility of stem cells, especially those of the hematopoietic system. A complete table of contents and free sample issue may be viewed on the Stem Cells and Development website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cellular Reprogramming, Tissue Engineering, and Human Gene Therapy. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers . website.